Med. Chem. Commun. 2016, 7, 224-229.

Efficient synthesis of novel disubstituted pyrido[3,4-b]pyrazines for the design of protein kinase inhibitors.

Bioorg. Med. Chem. Lett. 2014, 24, 3748-3752.

Discovery of (7-aryl-1,5-naphthyridin-2-yl)ureas as dual inhibitors of ERK2 and Aurora B kinases with antiproliferative activity against cancer cells.

ChemMedChem 2014, 9, 217-232.

Discovery of 7-Aryl-Substituted (1,5-Naphthyridin-4-yl)ureas as Aurora Kinase Inhibitors. 

 Eur. J. Med. Chem., 2012, 58, 543-556. 

Synthesis and biological evaluation of 2,3-diarylimidazo[1,2-a]pyridines as antileishmanial agents.

Synthesis, 2012, 44, 69-82.  

A convenient synthesis of novel 2,8-disubstituted pyrido[3,4-b]pyrazines possessing biological activity.

Synthesis, 2011, 5, 794-806.

Preparation of novel 2,3,8-trisubstituted pyrido[3,4-b]pyrazines and pyrido[2,3-b]pyrazines.

Bioorg. Med. Chem., 2009, 17(18), 6715-6727.

Synthesis and structure-activity relationships of N-aryl(indol-3-yl)glyoxamides as antitumor agents.

 J. Enz. Inh. Med. Chem.2008, 23(5), 686-695.

Side chain modifications of (indol-3-yl)glyoxamides as antitumor agents.

Synthèse et évaluation pharmacologique de composés indoliques et pyridopyraziniques à visée antitumorale.

Nantes, date de soutenance : 18 octobre 2005.